跳转至内容
Merck
CN

主要文件

查看所有文档

跳至

A0368000

阿米卡星

European Pharmacopoeia (EP) Reference Standard

登录查看公司和协议定价

关于此项目

经验公式（希尔记法）:
C22H43N5O13
CAS Number:
37517-28-5
分子量:
585.60
EC 号:
253-538-5
MDL编号:
MFCD01844966
UNSPSC代码:
41116107
NACRES:
NA.24
产品A0368000监管中，请联系销售询价或购买 联系客户支持
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

pharmaceutical primary standard

API类

amikacin

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

包装形式

neat

SMILES字符串

N([C@H]1[C@@H]([C@H]([C@@H]([C@H](C1)N)O[C@H]3O[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CN)O)O[C@H]2O[C@@H]([C@H]([C@@H]([C@H]2O)N)O)CO)C(=O)[C@@H](O)CCN

InChI

1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1

InChI key

LKCWBDHBTVXHDL-RMDFUYIESA-N

正在寻找类似产品? 访问 产品对比指南

比较类似商品

查看完整比较结果

显示差异

1 of 4

此商品
A0365900Y0001117C0684000
vibrant-m

A0368000

Amikacin

Amikacin sulfate European Pharmacopoeia (EP) Reference Standard

A0365900

Amikacin sulfate

Amikacin for system suitability European Pharmacopoeia (EP) Reference Standard

Y0001117

Amikacin for system suitability

vibrant-m

C0684000

Cefixime

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

manufacturer/tradename

EDQM

manufacturer/tradename

EDQM

manufacturer/tradename

EDQM

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

format

neat

format

neat

format

neat

format

neat

API family

amikacin

API family

amikacin

API family

amikacin

API family

cefixime

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Amikacin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Exclamation mark
GHS07

警示用语：

Warning

危险声明

H317

预防措施声明

P280

危险分类

Skin Sens. 1

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

    • 历史批次信息供参考:

    分析证书(COA)

    Lot/Batch Number

    It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

    如需帮助，请联系 客户支持

    已有该产品？

    在文件库中查找您最近购买产品的文档。

    访问文档库

    A Bruce Montgomery et al.
    Antimicrobial agents and chemotherapy, 58(7), 3714-3719 (2014-04-23)
    The amikacin-fosfomycin inhalation system (AFIS) is a combination of 2 antibiotics and an in-line nebulizer delivery system that is being developed for adjunctive treatment of pneumonia caused by Gram-negative organisms in patients on mechanical ventilation. AFIS consists of a combination
    M P Goren et al.
    The Pediatric infectious disease journal, 8(5), 278-282 (1989-05-01)
    A three-drug antibiotic regimen including vancomycin and amikacin has been recommended as effective treatment in clinical settings in which Gram-positive bacteremias are a serious problem. To determine if vancomycin potentiates the tubular proteinuria associated with amikacin therapy, we studied febrile
    P Van der Auwera
    The Journal of antimicrobial chemotherapy, 27 Suppl C, 63-71 (1991-05-01)
    The pharmacokinetic parameters of amikacin given once daily were compared to those of amikacin given bd at different daily dosages. In adult patients, 'peak' serum concentrations (30 min after 30 min infusion) were linearly proportional to the dose given with
    Sophia B Georghiou et al.
    PloS one, 7(3), e33275-e33275 (2012-04-06)
    Rapid molecular diagnostics for detecting multidrug-resistant and extensively drug-resistant tuberculosis (M/XDR-TB) primarily identify mutations in Mycobacterium tuberculosis (Mtb) genes associated with drug resistance. Their accuracy, however, is dependent largely on the strength of the association between a specific mutation and
    Amikacin.
    R D Meyer
    Annals of internal medicine, 95(3), 328-332 (1981-09-01)
    查看所有相关文献

    我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

    联系客户支持